Gilead Sciences (GILD) Other financing activities (2009 - 2026)

Gilead Sciences has reported Other financing activities for 18 years, with the latest figure at -$179.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities fell 1.7% year-over-year to -$179.0 million; the trailing twelve-month figure through Mar 2026 stood at -$443.0 million (down 29.91% YoY), and the FY2025 full-year result was -$440.0 million, down 56.58% from the prior year.
• Other financing activities for Q1 2026 stood at -$179.0 million, down from -$63.0 million in the prior quarter.
• The five-year high for Other financing activities was -$14.0 million in Q2 2022, with the low at -$179.0 million in Q1 2026.
• Historically, Other financing activities has averaged -$79.5 million across 5 years, with a median of -$64.0 million in 2025.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 133.33% — and 2024, when it advanced 14.07%.
• Gilead Sciences' Other financing activities stood at -$23.0 million in 2022, then slumped by 47.83% to -$34.0 million in 2023, then slumped by 38.24% to -$47.0 million in 2024, then sank by 34.04% to -$63.0 million in 2025, then tumbled by 184.13% to -$179.0 million in 2026.
• The last three Other financing activities figures came in at -$179.0 million (Q1 2026), -$63.0 million (Q4 2025), and -$137.0 million (Q3 2025), per Business Quant data.